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Abstract
Purpose: There is increasing recognition that the global
wellbeing of patients with chronic neurological disease is an
important outcome in research and clinical practice alike.
Many studies involving individuals with multiple sclerosis have
demonstrated that the overall wellbeing is not a simple
manifestation of impairment or disability. The strongest
correlations with health-related quality of life appear to be
patient rated emotional adjustment to illness and patient rated
handicap. In recent years, health-related quality of life
questionnaires that measure the physical, social, emotional,
and occupational impact of illness have been developed and
validated in populations with MS. Most questionnaires are
now available in a range of languages. This development is
likely to lead to increasing recognition of neuropsychiatric
complications of MS in clinical practice and better quantifica-
tion of treatment responses in clinical trials.
Conclusion: Further work is required to decide which scale is
most suited to which purpose. Assessment of multiple
sclerosis-specific health-related quality of life should be
included in future clinical trials to provide a complete picture
of patients’ health status.
Introduction
Multiple sclerosis (MS) is a chronic neurological
disease characterized by macroscopic and microscopic
areas of demyelination, linked with a broad spectrum
of physical and social impairments. The combination
of a progressive and unpredictable disease process
creates an uncommonly stressful illness which power-
fully impacts upon the quality of life (QoL) of both
the patients and their relatives.1 – 3
QoL is not a new concept and early reference can be
found in Greek literature. In its widest sense it embraces
all aspects of well being and includes social, emotional,
economic and cultural facets of our lives. Health Related
QoL (HRQoL), as distinct from general QoL, is concep-
tualized as those aspects of life quality or function which
are influenced by health status. This is broadly compati-
ble with the World Health Organisation definition of
health, namely that health is ‘a state of complete physi-
cal, mental and social well-being and not merely the
absence of disease or infirmity’. However, the term
HRQoL is more specific and is based on health dimen-
sions which can be measured. This ability to measure
HRQoL in individuals over time brings important bene-
fits. Quantifying HRQoL in different populations can
identify subgroups with poor physical or mental health
and can assist with interventions that may improve their
health. Assessment of HRQoL is increasingly important
for clinical research, clinical practice, and the decision-
making process in health policy.4 – 7
The interest in HRQoL in MS is very recent. For
many years research on the impact of MS was limited
to an examination of the concepts of impairment and
disability.8 The first paper that analysed the HRQoL
in MS patients was published in 1992. In this landmark
study, HRQoL was measured in 68 patients with MS,
164 patients with inflammatory bowel disease, and 75
patients with rheumatoid arthritis.9 HRQoL was lowest
in the MS group. Over the last decade the literature on
HRQoL in MS has grown exponentially. This has
encompassed a growth of descriptive studies about the
physical, emotional and social consequences of MS;
the development of MS specific HRQoL instruments;
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and most recently an examination of the effects of
disease-modifying therapies on HRQoL in MS
patients.10 The purpose of this article is to review this
literature concerning the impact of MS on HRQoL.
Method
We conducted a literature review using the principles
of evidence based medicine.11 We used the text search
terms (multiple sclerosis or MS) and (quality of life or
QoL or handicap or function or participation) to identi-
fy all relevant English papers between 1966 and April
2003. We searched the electronic databases Medline,
Embase, Web of Science and PsychInfo. We also
contacted experts in the field and hand-searched a
number of neurological journals. We excluded studies
that did not discuss QoL and articles without primary
data (review articles). The search identified approxi-
mately 330 published papers covering the major studies
on this topic, of which 89 had enough suitable informa-
tion to be discussed in this review.
THE INFLUENCE OF MULTIPLE SCLEROSIS ON HEALTH-
RELATED QUALITY OF LIFE
MS is a condition that has great potential to nega-
tively affect HRQoL. Yet, it is important to acknowl-
edge the wide range of individual differences in
emotional and psychological adjustment to disease, even
after the most disabling of impairments.12 People with
MS report a lower life satisfaction than people without
illness.13 They also report a lower satisfaction with life
than people with several chronic illnesses including
inflammatory bowel disease and rheumatoid arthritis
as well as epilepsy and diabetes.9 – 14 Several features of
MS may uniquely contribute to low HRQoL.10, 15 – 19
Firstly, MS affects the integrity of normal physiological
functioning in a diverse number of areas including
neurological function (motor and sensory disturbances,
sphincter problems and sexual dysfunction), neuropsy-
chiatric function (cognitive impairment, mood disorder
and psychosis), and other areas (for example, mobility
and fatigue). Secondly, the disease is diagnosed primar-
ily in young adults, which maximally influences produc-
tivity and personal development. Thirdly, MS has an
unpredictable course, in which relapses and future
disability are difficult for sufferers to anticipate. This
makes it difficult for patients to maintain a sense of
control over their disease. Fourthly, there is currently
limited evidence for disease-modifying treatment and
no possibility of cure. Finally, there are problems acces-
sing the latest treatment due to inequalities in health
care provision and there is a risk of drug-induced
adverse effects. Thus it is imperative to be aware of
the wider needs of patients. Yet, paradoxically, the effect
of MS on HRQoL has often been widely overlooked in
routine clinical practice and in most clinical trials.
Instead, physicians have concentrated on the assessment
of physical disability in MS, perhaps best exemplified by
the Expanded Disability Status Scale of Kurtzke
(EDSS).20 Although the EDSS was a major break-
through it is now recognized to have psychometric
limitations, including relatively poor responsiveness,
and a narrow focus.21 Subsequently other scales have
been devised, such as the Multiple Sclerosis Functional
Composite.22 This is a multidimensional clinical
outcome measure that includes quantitative tests of leg
function/ambulation (Timed 25-Foot Walk), arm func-
tion (9-Hole Peg Test), and cognitive function (Paced
Auditory Serial Addition Test). However, disability
and handicap scales such as the EDSS and the Func-
tional Composite have other limitations. They rely on
assessment by neurologists rather than patients and they
also omit domains of health that contribute to overall
QoL. These are important points as clinicians and
patients do not agree on what aspects of the disease
are most important.23 Research shows that clinicians
are most concerned about the physical manifestations
of disease, whereas patients tend to identify role limita-
tions, cognition and emotional problems as the most
significant influences upon wellbeing.23, 24 A further
aspect overlooked by conventional scales is the huge
burden on families and informal caregivers. This burden
is under-studied and under-reported but is comparable
to the burden experienced by relatives of neurodegenera-
tive disease.23 There is probably a relationship between
carer and patient distress.25, 26 This suggests that the
opinion of MS patients and caregivers should be consid-
ered in clinical trials and that outcomes should be
widened to include domains which affect patient distress
and family stress, a philosophy incorporated within the
concept of HRQoL.27 As a complement to the assess-
ment of physical disability, physicians must also recog-
nise the need for instruments to evaluate general
health, emotional and social functioning. This apprecia-
tion has resulted in the development of a series of new
instruments to assess HRQoL some of which are generic
and some of which are specific to MS.28
GENERIC HRQOL INSTRUMENTS
Generic measures of HRQoL are measures that were
developed without a specific disease in mind and are
therefore applicable to a wide range of populations.
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The main advantage of generic HRQoL instruments is
their broad coverage and the fact that they allow
comparisons of different populations across studies. A
significant disadvantage is that they may not address
topics of particular relevance to MS patients such as
cognitive complaints. A consequence of their relatively
poor coverage of specific symptoms in MS is that they
are less responsive to treatment-induced changes than
MS-specific measures. Nevertheless, studies involving
generic HRQoL instruments have provided important
data. These include:
(1) The initial identification of broad areas impacted
by MS that had not previously been considered
by conventional clinical scales.10, 16, 18, 19, 28 – 32
(2) The demonstration that the HRQoL in patients
with MS is, on average lower than HRQoL in
control subjects or in patients with other
diseases.9, 13, 14, 33, 34
(3) Assessment of MS HRQoL in clinical trials.35 – 40
Table 1 shows a selection of the generic HRQoL
instruments that have been used in MS studies to date.
The most widely used generic instrument is the SF-36,
which is generally considered to be the gold standard
generic measure of health status and has been validated
cross-culturally in MS.44, 46 – 52 The SF-36 is a broad
measure of disease impact rated by sufferers themselves.
In MS all eight dimensions of QoL in the SF-36 are
reduced compared with the general population.29
However, longitudinal studies have highlighted several
limitations of the SF-36, including a relatively poor
responsiveness and contamination from changes in
physical disability.53 Moreover, when using the SF-36
in MS patients, summary scores should be reported with
caution.54 On the other hand, the SF-36 mental health
summary scales appear to overestimate mental health
in MS sufferers, despite a high prevalence of emotional
and cognitive disorders.55
TYPES OF MS-SPECIFIC HRQOL INSTRUMENTS
New MS-specific measures of HRQoL have been
developed in an attempt to reduce the weaknesses inher-
ent in the generic instruments (table 2). Once developed,
further work is required to translate them into different
languages, or explore their validity in different settings.
Multiple Sclerosis Quality of Life 54
The MSQOL-54 was the first MS-specific HRQoL
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(RAND 36-Item Health 1.0)60 as a core measure, supple-
mented with 18 additional items in the areas of health
distress (four items), sexual function (four items), satis-
faction with sexual function (one item), overall quality
of life (two items), cognitive function (four items),
energy (one item), pain (one item), and social function
(one item). The generic component enables a compari-
son of HRQoL in MS patients to those of other patient
populations and to the general population. The final
MSQOL-54 instrument, contains 52 items distributed
into 12 subscales along with two summary scores, and
two additional single-item measures. The subscales are:
physical function, role limitations – physical, role limita-
tions – emotional, pain, emotional well-being, energy,
health perceptions, social function, cognitive function,
health distress, overall quality of life, and sexual func-
tion. The summary scores are the physical health
composite summary and the mental health composite
summary. The single item measures are satisfaction with
sexual function and change in health. This instrument,
which was validated in one study including 183 MS
patients, has a good internal consistency and test-retest
reliability,56 but its validity and sensitivity to change
has been criticised.61
Disability and Impact profile
The Disability & Impact profile (DIP) has been
used in several studies.30, 62 – 66 This instrument, which
was validated in a sample of 73 MS patients, contains
three symptoms questions (pain, visible deformities
and worry about deterioration), as well as 36 ques-
tions in five areas: mobility, self-care, communication,
social activities and psychological status. The results
are presented in a profile of weighted scores that take
into consideration the ‘(dis)ability’ and ‘impact’
aspects. By means of this profile and by means of
so-called major disruptions of HRQoL, which are
defined as a loss on weighted score on more than
50%, the DIP provides indications for treatment and
care. Internal consistency and test reliability are high
for all scales of the DIP.30, 62 – 66
Functional Assessment of Multiple Sclerosis
The original version of the Functional Assessment of
Multiple Sclerosis (FAMS) instrument, which was vali-
dated in one sample of 433 MS patients, comprises 59
items capturing six main QoL domains: Mobility (7
items), Symptoms (7 items), Emotional Well-being (7
items), General Contentment (7 items), Thinking/Fati-
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All six FAMS subscales (44 items total) demonstrated
very good reliability. Areas of concern to MS patients
that do not fall in these six general domains are included
in the Additional Concerns subscale (15 items).15, 67, 68 An
analysis of this FAMS version, applied in a sample of
308 Spanish MS patients, showed high internal consis-
tency reliability if eight additional MS-specific items,
which had been initially excluded from the original
version, were included.69 The main limitation of the
original FAMS is that it is unduly weighted toward
psychosocial consequences of disease. In contrast, the
Spanish modified version of the FAMS instrument
includes additional items about MS symptoms, which
increases its validity and range of coverage.69, 70 In a
recent study, FAMS instrument has been recommended
for measuring QoL in MS patients instead of the
MSQoL-54, since this latter instrument suffers from
floor effects on physical health subscales.71 The original
version of the FAMS is a very useful disease-targeted
instrument to evaluate MS patients’ HRQoL.15, 67, 68
However, we feel that the modified FAMS offers a more
holistic assessment of neurological symptoms and
psychosocial complaints associated with MS in line with
published recommendations regarding specific HRQoL
instruments.57, 71
Hamburg Quality of Life Questionnaire in Multiple
Sclerosis
The Hamburg Quality of Life Questionnaire in Multi-
ple Sclerosis (HAQUAMS, in German) comprises 38
items. This instrument was validated in one study that
included 237 MS patients. Validity was supported by
correlation with FAMS. Reliability was high and satis-
fied psychometric standards. No floor or ceiling effects
have been found in either of the HAQUAMS subscales.
However, there is, as yet, no data about sensitivity to
change. Of note, the HAQUAMS discriminated
between MS patients with and without cognitive impair-
ment.72
Leeds Multiple Sclerosis Quality of Life
The Leeds Multiple Sclerosis Quality of Life
(LMSQoL) is a new eight-item instrument with a good
internal consistency and test-retest reliability. Moreover,
there are minimal floor or ceiling effects for the scale.
The instrument is also easy to use and practical to
administer in clinic or as a postal questionnaire. It also
measures a construct related to well-being, and thus
provides an useful adjunct to the measurement of
outcome in MS.73, 74
Multiple Sclerosis Impact Scale
The Multiple Sclerosis Impact Scale (MSIS-29)
consists of 29 items that measure the physical (20
variables) and psychological (nine variables) impact
of MS. The instrument, which was validated in 766
MS patients, has shown good validity, small floor
and ceiling effects, high internal consistency, high test
re-test reliability and preliminary evidence of good
responsiveness.76 These results suggest that this instru-
ment is a clinically useful and scientifically robust
patient-based outcome measure. A recent study has
demonstrated that the psychometric properties of
the MSIS-29 are consistent across hospital based
samples, and similar to those in the community
samples.76
Multiple Sclerosis Quality of Life Inventory
The Multiple Sclerosis Quality of Life Inventory
(MSQLI) is a modular MS-specific HRQoL instru-
ment consisting of the Health Status Questionnaire
(SF-36), supplemented by nine symptom-specific
measures (covering fatigue, pain, bladder function,
bowel function, emotional status, perceived cognitive
function, visual function, sexual satisfaction, and
social relationships). The MSQLI was validated in
one study that included 300 MS patients. The level
of validation was extensive, showing that the internal
consistency of the total MSQLI and the subscales
was good, with one exception (social relationships),
and that the instrument has good construct validity.
One advantage to using the MSQLI is that psychome-
trically sound short scales are available. Furthermore,
when compared to the FAMS and the MSQoL-54, the
MSQLI was most flexible since its components are
separable.77
RAYS
The RAYS scale has three subscales that cover differ-
ent dimensions of HRQoL (physical, psychological, and
social-familial) and each includes 15 self-report items
scored from one (best) to four (worse). Validation was
achieved through administration of the scale to 50
randomly selected MS patients and to 50 age, sex-,
education- and family status-matched healthy controls.
The instrument demonstrated high internal consistency
and significant discriminative value. The RAYS
subscales correlated significantly with the SF-36 scales,
and the physical RAYS scale was moderately correlated
with EDSS.78
Impact of MS on health-related quality of life
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Pfennings HRQoL Instrument
Pfennings et al.79 administered the SF-36; COOP/
WONCA Charts—the COOP Charts evaluate overall
patient functioning through the use of pictorial repre-
sentations of functioning levels;80 and DIP to 162 MS
patients. Factor analyses identified two underlying
dimensions of HRQoL, relating to ‘physical function-
ing’ and ‘psychological functioning’. Selection of the
three highest loading reliable scales on each factor
resulted in a final questionnaire consisting of three scales
of the SF-36 and three scales of the DIP. In total 40
items were selected, requiring about 10 min to complete.
This instrument is brief and adequately measures two
dimensions of HRQoL.79
Quality of Life-Index MS-Version
The Quality of life-Index (QLI) was developed by
Ferrans & Powers to measure quality of life in terms
of satisfaction with life.81 The QLI measures both satis-
faction and importance regarding various aspects of life.
QLI produces five scores: quality of life overall and in
four domains (health and functioning, psychological/
spiritual domain, social and economic domain, and
family). A number of versions of the QLI have been
developed for use with various disorders, including
MS. The QLI MS-version consists of 72 items covering
physical symptoms, emotional and social sphere, sexual
problems, and fatigue.82 – 84
Performance Scales
The Performance Scales are 7-level categorical rating
scales with subscales for mobility, hand function, vision,
fatigue, cognitive, bladder/bowel, sensory and spasticity
symptoms. The total number of items is 21. Impact on
work productivity is assessed with separate items. This
instrument has documented test-retest reliability and
internal consistency reliability. However, it may be
subject to recall bias as patient is asked to compare level
of disability to function prior to disease.85
HRQOL ASSESSMENT AS END-POINTS IN MS CLINICAL TRIALS
Rapid development of potentially disease-modifying
treatments has led to multiple drug trials in patients with
both relapsing-remitting and secondary progressive MS.
Unfortunately, not all groups have recognized the need
to measure the possible benefits of treatment upon
broadly defined patient and caregiver well-being. In
the last few years, HRQoL assessments have gradually
been incorporated into randomized controlled trials to
evaluate the effectiveness of MS therapies, such as inter-
feron. Although the use of HRQoL scales provides addi-
tional information that is important for treatment
decisions and resource allocation, only a handful of
Trialists have employed these measures as primary or
secondary end-point in MS studies (table 3).
HRQoL findings in randomized clinical trials of new drug
treatments for MS
Despite the advent of several MS-specific HRQoL
instruments, all except one of the studies of interferon
b in relapsing-remitting MS patients have used a generic
instrument. Results vary, ranging from no effect on
HRQoL to definite improvement in physical dimen-
sions. The reasons for the discrepancy in results is
almost certainly related to methodological variations
in the samples and their follow-up compounded by the
use of different HRQoL instruments. Two studies have
evaluated the effect of interferon b on secondary
progressive MS patients’ HRQoL. In both studies,
several HRQoL dimensions improved.39, 96 There is one
study that has evaluated the HRQoL of MS patients
who had suffered a relapse treated with intravenous
methylprednisolone. There was statistically significant
early improvement of EDSS and the Incapacity Status
Scale scores and a trend towards improvement in the
SF-36 physical and mental composites short of statisti-
cal significance. These results suggest that improvement
of impairments and disability after treatment with intra-
venous methylprednisolone for a relapse of MS occurs
early, while improvement of subjective health status is
delayed.32
HRQoL findings in randomized clinical trials of non-
pharmacological trials in MS
Exercise training as well as physical rehabilitation,
and T’ai chi programme are known to improve MS
patients’ HRQoL (see table 3). Therefore, this data
supports the suggestion that patients should be encour-
aged to engage in regular daily exercise and patients who
have significant disability should be offered rehabilita-
tion programmes.
RELATIONSHIP BETWEEN CLINICAL VARIABLES AND HRQOL
IN MS
The relationship between clinical variables and
HRQoL in MS should be of considerable interest to
clinicians since a knowledge of this relationship may
J. Benito-León et al.
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Table 3 Therapeutic interventions on MS in which a HRQoL instrument has been used
Therapy MS type Patients Duration Instrument Results
Petajan et al.86 Aerobic training RR 54 15 weeks SIP All domains improved
Jønsson et al.87 Rehabilitation programme PP/SP 43 NS LLQ All domains improved
Di Fabio et al.88 Outpatient Rehabilitation
programme
PP/SP 31 12 months SF-36 The treatment group showed
improvements in six
dimensions that were not
improved in the wait-listed
group
Schwartz et al.35 Interferon b 1b RR 79 12 months Q-TWIST No effect on the number of
months of quality-adjusted
time





Gianino et al.90 Intrathecal baclofen for
spasticity
SP 15 12 months SF-36 No effect on QLI scores, but
the SIP revealed significant
changes in the total score as
well as the physical and
psychosocial subscales.
Nortvedt et al.36 INF a 2-a RR 97 12 months QLI, SIP The adverse events
negatively affected the
patients’ HRQoL
Husted et al.91 T’ai chi programme PP/SP 19 8 months SF-36 Patients experienced
improvements in vitality,
social functioning, mental
health, and ability to carry
out physical and emotional
roles.
Solari et al.92 Inpatient rehabilitation RR 50 15 weeks SF-36 Mental domain improved at
3 and 9 weeks
Freeman et al.93 Inpatient rehabilitation PP/SP 50 12 months SF-36 The effect of inpatient
rehabilitation on disability
and HRQoL declined after
discharge
Rice et al.37 Interferon b 1b RR 117 60 months SF-36 Physical, social and health
dimensions improved
especially those with an
EDSS 5 3.0
Parkin et al.94 Interferon b 1b RR 102 12 months MSQoL-54,
EQ-5D
Interferon b 1b produces
important occasional short
term QoL gains, but small
gains in quality-adjusted life
years and large additional
costs
Arnoldus et al.38 Interferon b RR 51 6 months SF-36 Physical dimensions
improved. More pain within
the first month of treatment
Freeman et al.39 Interferon b 1b SP 718 36 months SIP Physical dimension
improved
Bethoux et al.32 Methylprednisolone RR 24 3 months SF-36 Trends for improvement of
physical and mental
composites
Mathiowetz et al.95 Energy conservation course RR 54 19 weeks SF-36 HRQoL improved
Cohen et al.96 Intramuscular
interferon b 1a
SP 436 24 months MSQLI Benefit on eight of 11
MSQLI subscales
Patti et al.97 Outpatient rehabilitation
programme
PP/SP 58 6 weeks SF-36 All domains improved
Vermersch et al.40 Intramuscular interferon b
1a
RR 121 12 months SF-36 No negative effect on MS
patient’s HRQoL.
EQ-5D: European Quality of Life Scale (EuroQoL-5D); LLQ: Laman & Lankhorst Questionnaire; RR: Remitting-Relapsing; SP: Secondary
Progressive; PP: Primary Progressive; SF-36: 36-Item Short-Form Health Survey; QLI: Ferrans and Powers Quality of Life Index; SIP: Sickness
Impact Profile; MSQLI: Multiple Sclerosis Quality of Life Inventory; MSQoL-54: Multiple Sclerosis Quality of Life 54; NHP: Nottingham Health
Profile; NS: Non-stated.
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permit identification of those aspects of disease most
closely linked with patient-rated distress and thus
inform targeted treatment.
Relationship between neurological impairment and
disability and HRQoL
A substantial body of evidence demonstrates that
HRQoL in MS is associated with impairment and
disability as measured by neurological symptoms, the
EDSS or the Multiple Sclerosis Functional Compo-
site.98 – 106 However, the strength of the correlation varies
enormously depending on the methodology of each indi-
vidual study. In a Canadian study involving 198 MS
patients, QoL scores for all eight scales of the SF-36
were substantially reduced early in the disease.107 In
another study involving 98 patients with MS, measures
of bodily function, but not EDSS per se was correlated
with QoL scores on the SF-36.108 It is possible to
conclude that neurological impairment and disability
only contribute a modest proportion to overall HRQoL.
However, this association is not negated when other
important variables such as fatigue, cognitive impair-
ment, anxiety and depression are accounted for.101 Thus
disability appears to have an independent, if modest,
contribution to overall HRQoL and over time other
variables such as copying style, neuropsychiatric compli-
cations and support probably become more signifi-
cant.21, 101
Given the widespread use of neuroimaging as a
marker of disease severity, it should be no surprise that
some groups have reported a similar modest link with
HRQoL. For example, in a recent magnetic resonance
imaging (MRI) study, brain lesions and atrophy were
associated with impaired several domains of HRQoL
including sexual dysfunction, poor mental health, and
functional limitations. These correlations were stronger
for hypointense lesions and atrophy on T1-weighted
images than for hyperintense lesions on T2-weighted
images.98 What is not yet known, is whether neuroima-
ging can explain a significant proportion of HRQoL
over and above that explained by a clinically based
patient evaluation.
Relationship between disease course and subtype and
HRQoL
There is some debate regarding the influence of the
physical symptoms of MS on HRQoL. While, those
living a longer time with MS are likely to have increased
levels of disability, poor psychological adjustment to
MS is not necessarily related to a longer disease dura-
tion or high disease severity.109 – 111 Nevertheless, disease
course may influence HRQoL. Specifically, the more
aggressive the disease course, the lower the HRQoL.
Thus, all other factors being equal, a primary progres-
sive subtype has more negative impact than a secondary
progressive subtype which in turn has more negative
impact than a relapsing – remitting subtype.30, 70 It must
also be recognised that all subtypes have a haphazard
element which is difficult for patients to cope with.
Relationship between cognitive impairment and HRQoL
The prevalence of cognitive impairment in MS is esti-
mated at 45 – 65% and is a feature of all disease
subtypes, including groups of patients with normal
appearing white matter.112 Varying degrees of mild
cognitive impairment are much more common than
frank dementia. Patients with cognitive impairment are
less likely to be professionally and socially active and
are more dependent on caregivers than cognitively intact
MS patients.113 The majority of studies clearly show an
association between cognitive impairment and global
HRQoL. For example, executive dysfunction and
memory impairment are related to a worsening of
HRQoL (in particular the physical functioning and
mental health subscales of SF-36).114 In line with these
results, in a recent study involving 209 MS patients
our group found that the worse cognitive functioning
the lower HRQoL.70 However one notable exception
found an inverse relationship between HRQoL and
cognitive function. Severely affected MS patients with
autobiographical impaired memory reported signifi-
cantly better HRQoL.115 One explanation may be the
interplay with insight. Patients with significantly
impaired cognition tend to have reduced insight into
their condition. In this study, patients with normal auto-
biographical memory reported the highest levels of
depression and the lowest levels of HRQoL. Thus it
may be that the negative aspects of impaired cognition
on HRQoL were offset by poor insight and the advan-
tages of good cognition on HRQoL were confounded
by low mood.
Relationship between depression and HRQoL
Mood disorders, particularly depression and anxiety
are very common in MS patients but frequently over-
looked.116 Depression shows one of the strongest links
with lower HRQoL scores in several studies, indepen-
dent of the clinical course or disability status of MS
patients.70, 116 – 122 MS depressed patients scored worse
in the energy, mental health, cognitive function, overall
J. Benito-León et al.
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QoL, sexual and emotional function dimensions than
non-depressed MS patients.120 In a recent paper, a
strong inverse correlation was found between the physi-
cal and mental dimensions and the depressive symptoms
was found using the MSQOL-54 and the Hamilton
Depression Rating Scale.121 Furthermore, a highly
significant correlation between depressive symptoms
using the Zung Depression Scale, as well as anxiety
using the Zung Anxiety Scale, and the self-assessed qual-
ity of life measured with a generic instrument (QoL
index).122 The negative impact of depression on HRQoL
has also been demonstrated by our group.70 Bakshi et
al.119 found that depression was significantly associated
with lower HRQoL scores concerning health perception,
sexual dysfunction, health distress, mental health, over-
all QoL, emotional dysfunction, and limitations due to
emotional problems. In this study, associations
remained significant after adjusting for confounders
such as severity of neurologic disability and fatigue.
However, there is a conceptual problem in understand-
ing the link between mood and HRQoL. Most scales
of HRQoL include ratings of mood, satisfactions and
somatic items which are also symptoms of depression.
Fundamentally, patients who are currently depressed
will give a greater negative evaluation of their wellbeing
than those who are not depressed, whether or not a
physical illness is also present. Thus it is unavoidable
that there will be some overlap between ratings of low
mood and HRQoL. However, the association may still
prove clinically useful if the depression provides a
contribution to HRQoL beyond that explained by other
variables or conversely if measures of HRQoL allow
greater recognition of depression.
Relationship between fatigue and HRQoL
The subjective experience of fatigue is one of the most
common and disabling symptoms in MS patients. Fati-
gue is certainly linked with reduced HRQoL, however,
the precise way in which fatigue impacts on HRQoL
has not been clearly defined. In a recent study involving
patients with MS, fatigue as well as depression were
independently associated with impaired HRQoL.123
Recently, these findings have been corroborated by
our group.124 Accumulating work suggests that the
recognition and treatment of fatigue can improve
HRQoL.103 The overlap of fatigue and depression may
be a methodological concern in the assessment of either.
However, in a longitudinal assessment of a cohort of 98
MS patients, depression did not predict the later mental
fatigue nor was depression predicted by preceding fati-
gue experiences.125
Conclusions
Several factors conspire to make MS a disease with
major psychological and social ramifications for both
patients and their caregivers. These include the onset
of MS during the most productive years of life, the
uncertain and unstable natural history of the condition,
the diffuse effects on the CNS, especially on higher func-
tions, the relative preservation of insight and the
absence of convincing disease-modifying treatment.
Historically, the assessment of MS has encompassed
measures that assess impairment and disability but has
omitted important components of HRQoL as volun-
teered by sufferers themselves. In the last few years, a
greater understanding of HRQoL in MS has facilitated
several clinical advances. Generic and specific HRQoL
instruments have been developed and validated in order
to more accurately determine the global impact of MS
on an individual and along with the relevant predictive
factors. Clinical trials of new pharmacological and
non-pharmacological treatments have begun to incorpo-
rate HRQoL measures as primary or secondary
outcome points. There is now considerable interest in
understanding the predictors of HRQoL. Perhaps
surprisingly, established physician rated measures of
impairment and disability are not as closely linked with
HRQoL as patient ratings of handicap and mood. Of
particular note, depression has one of the strongest asso-
ciations with low HRQoL and also influences engage-
ment in rehabilitation and level of distress in
caregivers. These findings have been replicated in other
neurological diseases.126 – 128 Greater awareness of such
influences upon HRQoL is likely to lead to better recog-
nition and treatment of previously overlooked neurop-
sychiatric complications. Yet the overlap between
neuropsychiatric syndromes and HRQoL in its current
form, remains a difficult conceptual area. For example,
cognitive deficits are a manifestation of MS and a
predictor of poor HRQoL but such complaints, when
severe, may interfere with self-evaluation. Similarly
low mood is a common complication of MS and logi-
cally linked with low HRQoL, but depression is likely
to disproportionately affect global self-evaluation and
hence influence different domains of HRQoL. A simple
solution is to allow any complaint, or limitation into a
global rating of HRQoL, accepting that each complica-
tion adds to the burden of disease as a whole. A more
challenging solution is to ask how much does the
complication uniquely interfere with that individual’s
premorbid expectation of their ability to act, think and
feel. For example, one might equally ask to what extent
does low mood interfere with a patient’s ability to enjoy
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seeing friends, as to what extent does the ataxia interfere
with the ability to leave the house, unaided. In this sense
the impact of a disease will always be more than the
total collection of symptoms using any method of
measurement. What is more, only the sufferers them-
selves can attempt to estimate the past, present and
anticipated future losses that are causing distress.
We have seen a proliferation of generic and specific
HRQoL scales for MS over the last 10 years. It is now
time to examine their properties carefully in order to
find the scales most suitable for specific situations. It is
unlikely that one scale will satisfy all requirements. Most
notably clinicians need a concise scale, that can be admi-
nistered by members of a multidisciplinary team and
junior medical staff. Researchers generally need a more
comprehensive scale that is particularly sensitive to
change. Future developments in this field will include a
better delineation of the modifying variables in HRQoL.
These may include the impact of doctor-patient commu-
nication, availability of local resources, the effect of self-
help and education strategies, the influence of support
and the effects of individual differences in coping and
adjustment to illness. HRQoL is now established as an
important outcome variable in therapeutic trials in MS
where it often highlights areas of most concern to
patients and care-givers. The concept of HRQoL is
equally important in clinical practice as it emphasizes
the importance of neuropsychiatric and social complica-
tions as well as the traditional impairment and disability
domains that form part of the total burden experienced
by patients with MS.
References
1 Stenager E, Stenager EN, Knudsen L, Jensen K. Multiple sclerosis:
the impact on family and social life. Acta Psychiatrica Belgica 1994;
94: 165 – 174.
2 Rivera-Navarro J, Morales JM, Benito-León J. Informal caregiv-
ing in multiple sclerosis patients: Data from the demyelinating
diseases study group from Madrid. Disability and Rehabilitation;
(in press).
3 Lynch SG, Kroencke DC, Denney DR. The relationship between
disability and depression in multiple sclerosis: the role of
uncertainty, coping, and hope.Multiple Sclerosis 2001; 7: 411 – 416.
4 Patrick DL, Bergner M. Measurement of health status in the 1990s.
Annual Review of Public Health 1990; 11: 165 – 183.
5 Egli H. What constitutes quality of life? Methodological con-
siderations and suggestions for clinical practice. Scandinavian
Journal of Gastroenterology 1987; 22(Suppl): S87 – S9.
6 Carr AJ, Gibson B, Robinson PG. Measuring quality of life: Is
quality of life determined by expectations or experience? BMJ
2001; 322: 1240 – 1243.
7 Miller DM. Health-related quality of life. Multiple Sclerosis 2002;
8: 269 – 270.
8 Kurtzke JF. On the Evaluation of Disability in Multiple Sclerosis.
Neurology 1961; 11: 686 – 694.
9 Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality
of life in multiple sclerosis. Comparison with inflammatory bowel
disease and rheumatoid arthritis. Archives of Neurology 1992; 49:
1237 – 1242.
10 Benito-León J, Martı́nez-Martı́n P. Calidad de vida relacionada
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